1731. |
1732. |
1733. |
1734. Jugoslavija i ambivalentnost ekonomske saradnje Jug-Jug u sedamdesetim i osamdesetim godinamaJure Ramšak, 2024, original scientific article Abstract: Na vrhuncu napora zemalja u razvoju da uspostave Novi međunarodni ekonomski poredak, Jugoslavija je, kao jedna od vodećih članica Pokreta nesvrstanih i Grupe 77 zemalja u razvoju (G-77), nastojala da dokaže da je moguće uspostaviti novi obrazac odnosa između industrijski razvijenih zemalja, kojima je delimično i sama pripadala i saveznika iz ove koalicije, čije su ekonomske baze još uvek bile u fazi izgradnje. U skladu sa određenim dominantnim grupama unutar UN-a, jugoslovenska teorija razvoja spajala je marksistička sa neoklasičnim ekonomskim shvatanjima u ambiciozan program globalne reforme koja je odstupala od stavova kapitalističkih i socijalističkih velesila. Ipak, u isto vreme, ova vizija globalizacije morala je da se nosi sa ideološkim, geopolitičkim i ekonomskim uticajem novonastale neoliberalne revolucije, koja je početkom osamdesetih počela bitno sužavati prostor za manevrisanje. Pored programskih načela sadržanih u zvaničnim dokumentima, ovaj rad prati i konkretne oblike jugoslovenske bilateralne ekonomske saradnje sa pojedinim afričkim zemljama.
Published in DiRROS: 06.05.2024; Views: 503; Downloads: 188
 Full text (155,61 KB)
This document has many files! More... |
1735. Bioresorbability dependence on microstructure of additivelly- manufactured and conventionally-produced Fe-Mn alloysMatjaž Godec, Jakob Kraner, Danijela Anica Skobir Balantič, Irena Paulin, Damjana Drobne, Veno Kononenko, Aleksandra Kocijan, Paul J. McGuiness, Črtomir Donik, 2024, original scientific article Keywords: Fe-Mn alloy, laser powder bed fusion, bioresorbable, microstructure, corrosion behaviour, biocompatibility
Published in DiRROS: 06.05.2024; Views: 494; Downloads: 359
Full text (12,78 MB)
This document has many files! More... |
1736. Evolution of RMA in SloveniaPrimož Petek, Tjaša Baloh, Vanda Baloh, 2024, independent scientific component part or a chapter in a monograph Abstract: This chapter outlines the research management and administration (RMA) as a profession and work field in Slovenia. Thus, we present an overview of the Slovenian research system, describing how this system has evolved over time. In addition, we explain the emerging need for RMA skills, including its self-organisation component and the challenges that lie ahead. A section is dedicated to Slovenian RMA demographics using RAAAP-2 and RAAAP-3 surveys. The conclusions of the chapter focus on a forecast for the future of RMA in Slovenia and several possible paths to follow for its community.
Keywords: Slovenia, research management and administration, professionalisation, KOsRIS II, RAAAP, research ecosystem
Published in DiRROS: 30.04.2024; Views: 559; Downloads: 232
Full text (734,17 KB)
This document has many files! More... |
1737. Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myelomaDirk Rades, Antonio J. Conde-Moreno, Jon Cacicedo, Barbara Šegedin, Volker Rudat, Steven E. Schild, 2016, original scientific article Abstract: Uncertainty exists whether patients with spinal cord compression (SCC) from a highly radiosensitive tumor require decompressive spinal surgery in addition to radiotherapy (RT). This study addressed the question by evaluating patients receiving RT alone for SCC from myeloma. Patients and methods. Data of 238 patients were retrospectively analyzed for response to RT and local control of SCC. In addition, the effect of RT on motor function (improvement, no further progression, deterioration) was evaluated. Overall response was defined as improvement or no further progression of motor dysfunction. Prior to RT, patients were presented to a neurosurgeon for evaluation whether upfront decompressive surgery was indicated (e.g. vertebral fracture or unstable spine). Results. In the entire cohort, the overall response rate was 97% (53% improvement plus 44% no further progression). Following RT, 88% of the patients were able to walk. Of the 69 non-ambulatory patients 44 patients (64%) regained the ability to walk. Local control rates at 1, 2 and 3 years were 93%, 82% and 82%, respectively. A trend towards better local control was observed for patients who were ambulatory before starting RT (p = 0.08) and those with a more favorable performance status (p = 0.07). Conclusions. RT alone provided excellent response rates, functional outcomes and local control in patients with SCC from myeloma. These results should be confirmed in a prospective randomized trial.
Keywords: myeloma, spinal cord compression, radiotherapy
Published in DiRROS: 30.04.2024; Views: 486; Downloads: 270
Full text (585,22 KB)
This document has many files! More... |
1738. Uncertainties in target volume delineation in radiotherapy : are they relevant and what can we do about them?Barbara Šegedin, Primož Petrič, 2016, original scientific article Abstract: Modern radiotherapy techniques enable delivery of high doses to the target volume without escalating dose to organs at risk, offering the possibility of better local control while preserving good quality of life. Uncertainties in target volume delineation have been demonstrated for most tumour sites, and various studies indicate that inconsistencies in target volume delineation may be larger than errors in all other steps of the treatment planning and delivery process. The aim of this paper is to summarize the degree of delineation uncertainties for different tumour sites reported in the literature and review the effect of strategies to minimize them. Conclusions. Our review confirmed that interobserver variability in target volume contouring represents the largest uncertainty in the process for most tumour sites, potentially resulting in a systematic error in dose delivery, which could influence local control in individual patients. For most tumour sites the optimal combination of imaging modalities for target delineation still needs to be determined. Strict use of delineation guidelines and protocols is advisable both in every day clinical practice and in clinical studies to diminish interobserver variability. Continuing medical education of radiation oncologists cannot be overemphasized, intensive formal training on interpretation of sectional imaging should be included in the program for radiation oncology residents.
Keywords: target volume, interobserver variability, delineation uncertainties, imaging
Published in DiRROS: 30.04.2024; Views: 725; Downloads: 546
Full text (904,32 KB)
This document has many files! More... |
1739. Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitorsTanja Jesenko, Lara Prosen, Maja Čemažar, Tjaša Potočnik, Gregor Serša, 2016, original scientific article Abstract: The aim of the study was to explore the effectiveness of electrochemotherapy (ECT) during the treatment of melanoma patients with BRAF inhibitors. Its effectiveness was tested on BRAF mutated and non-mutated melanoma cells in vitro and in combination with BRAF inhibitors. Materials and methods. ECT with bleomycin was performed on two human melanoma cell lines, with (SK-MEL-28) or without (CHL-1) BRAF V600E mutation. Cell survival was determined using clonogenic assay to determine the effectiveness of ECT in melanoma cells of different mutation status. Furthermore, the effectiveness of ECT in concomitant treatment with BRAF inhibitor vemurafenib was also determined in BRAF mutated cells SK-MEL-28 with clonogenic assay. Results. The survival of BRAF V600E mutated melanoma cells was even lower than non-mutated cells, indicating that ECT is effective regardless of the mutational status of melanoma cells. Furthermore, the synergistic interaction between vemurafenib and ECT with bleomycin was demonstrated in the BRAF V600E mutated melanoma cells. Conclusions. The effectiveness of ECT in BRAF mutated melanoma cells as well as potentiation of its effectiveness during the treatment with vemurafenib in vitro implies on clinical applicability of ECT in melanoma patients with BRAF mutation and/or during the treatment with BRAF inhibitors.
Keywords: electrochemotherapy, BRAF inhibitors, vemurafenib, melanoma
Published in DiRROS: 30.04.2024; Views: 595; Downloads: 150
Full text (642,09 KB) |
1740. Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer : single center experienceJanja Ocvirk, Maja Ebert Moltara, Tanja Mesti, Marko Boc, Martina Reberšek, Neva Volk, Jernej Benedik, Zvezdana Hlebanja, 2016, original scientific article Abstract: Metastatic colorectal cancer (mCRC) is mainly a disease of elderly, however, geriatric population is underrepresented in clinical trials. Patient registries represent a tool to assess and follow treatment outcomes in this patient population. The aim of the study was with the help of the patients% register to determine the safety and efficacy of bevacizumab plus chemotherapy in elderly patients who had previously untreated metastatic colorectal cancer. Patients and methods. The registry of patients with mCRC was designed to prospectively evaluate the safety and efficacy of bevacizumab-containing chemotherapy as well as selection of patients in routine clinical practice. Patient baseline clinical characteristics, pre-specified bevacizumab-related adverse events, and efficacy data were collected, evaluated and compared according to the age categories. Results. Between January 2008 and December 2010, 210 patients with mCRC (median age 63, male 61.4%) started bevacizumab-containing therapy in the 1st line setting. Majority of the 210 patients received irinotecan-based chemotherapy (68%) as 1st line treatment and 105 patients (50%) received bevacizumab maintenance therapy. Elderly (% 70 years) patients presented 22.9% of all patients and they had worse performance status (PS 1/2, 62.4%) than patients in < 70 years group (PS 1/2, 35.8%). Difference in disease control rate was mainly due to inability to assess response in elderly group (64.6% in elderly and 77.8% in < 70 years group, p = 0.066). The median progression free survival was 10.2 (95% CI, 6.7%16.2) and 11.3 (95% CI, 10.2%12.6) months in elderly and < 70 years group, respectively (p = 0.58). The median overall survival was 18.5 (95% CI, 12.4%28.9) and 27.4 (95% CI, 22.7%31.9) months for elderly and < 70 years group, respectively (p = 0.03). Three-year survival rate was 26% and 37.6% in elderly vs. < 70 years group (p = 0.03). Overall rates of bevacizumab-related adverse events were similar in both groups: proteinuria 21/22 %, hypertension 25/19 %, haemorrhage 2/4 % and thromboembolic events 10/6 %, for elderly and < 70 years group, respectively. Conclusions. In routine clinical practice, the combination of bevacizumab and chemotherapy is effective and welltolerated regimen in elderly patients with metastatic colorectal cancer.
Keywords: metastatic colorectal cancer, bevacizumab, chemotherapy, elderly
Published in DiRROS: 30.04.2024; Views: 487; Downloads: 165
Full text (620,74 KB) |
